269 related articles for article (PubMed ID: 22219275)
1. SIRT1 protects against α-synuclein aggregation by activating molecular chaperones.
Donmez G; Arun A; Chung CY; McLean PJ; Lindquist S; Guarente L
J Neurosci; 2012 Jan; 32(1):124-32. PubMed ID: 22219275
[TBL] [Abstract][Full Text] [Related]
2. Sirt1/FoxO1-Associated MAO-A Upregulation Promotes Depressive-Like Behavior in Transgenic Mice Expressing Human A53T α-Synuclein.
Li Y; Jiao Q; Du X; Jiang H
ACS Chem Neurosci; 2020 Nov; 11(22):3838-3848. PubMed ID: 33155799
[TBL] [Abstract][Full Text] [Related]
3. Early start of progressive motor deficits in Line 61 α-synuclein transgenic mice.
Rabl R; Breitschaedel C; Flunkert S; Duller S; Amschl D; Neddens J; Niederkofler V; Rockenstein E; Masliah E; Roemer H; Hutter-Paier B
BMC Neurosci; 2017 Jan; 18(1):22. PubMed ID: 28143405
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich repeat kinase 2 regulates the progression of neuropathology induced by Parkinson's-disease-related mutant alpha-synuclein.
Lin X; Parisiadou L; Gu XL; Wang L; Shim H; Sun L; Xie C; Long CX; Yang WJ; Ding J; Chen ZZ; Gallant PE; Tao-Cheng JH; Rudow G; Troncoso JC; Liu Z; Li Z; Cai H
Neuron; 2009 Dec; 64(6):807-27. PubMed ID: 20064389
[TBL] [Abstract][Full Text] [Related]
5. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
[TBL] [Abstract][Full Text] [Related]
6. Prion-like propagation of human brain-derived alpha-synuclein in transgenic mice expressing human wild-type alpha-synuclein.
Bernis ME; Babila JT; Breid S; Wüsten KA; Wüllner U; Tamgüney G
Acta Neuropathol Commun; 2015 Nov; 3():75. PubMed ID: 26612754
[TBL] [Abstract][Full Text] [Related]
7. Inclusion body formation and neurodegeneration are parkin independent in a mouse model of alpha-synucleinopathy.
von Coelln R; Thomas B; Andrabi SA; Lim KL; Savitt JM; Saffary R; Stirling W; Bruno K; Hess EJ; Lee MK; Dawson VL; Dawson TM
J Neurosci; 2006 Apr; 26(14):3685-96. PubMed ID: 16597723
[TBL] [Abstract][Full Text] [Related]
8. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
9. Synphilin-1 attenuates neuronal degeneration in the A53T alpha-synuclein transgenic mouse model.
Smith WW; Liu Z; Liang Y; Masuda N; Swing DA; Jenkins NA; Copeland NG; Troncoso JC; Pletnikov M; Dawson TM; Martin LJ; Moran TH; Lee MK; Borchelt DR; Ross CA
Hum Mol Genet; 2010 Jun; 19(11):2087-98. PubMed ID: 20185556
[TBL] [Abstract][Full Text] [Related]
10. Caffeic acid reduces A53T α-synuclein by activating JNK/Bcl-2-mediated autophagy in vitro and improves behaviour and protects dopaminergic neurons in a mouse model of Parkinson's disease.
Zhang Y; Wu Q; Zhang L; Wang Q; Yang Z; Liu J; Feng L
Pharmacol Res; 2019 Dec; 150():104538. PubMed ID: 31707034
[TBL] [Abstract][Full Text] [Related]
11. p62 Deficiency Enhances α-Synuclein Pathology in Mice.
Tanji K; Odagiri S; Miki Y; Maruyama A; Nikaido Y; Mimura J; Mori F; Warabi E; Yanagawa T; Ueno S; Itoh K; Wakabayashi K
Brain Pathol; 2015 Sep; 25(5):552-64. PubMed ID: 25412696
[TBL] [Abstract][Full Text] [Related]
12. Prion-like transmission of α-synuclein pathology in the context of an NFL null background.
Rutherford NJ; Brooks M; Riffe CJ; Gorion KM; Howard JK; Dhillon JS; Giasson BI
Neurosci Lett; 2017 Nov; 661():114-120. PubMed ID: 28964772
[TBL] [Abstract][Full Text] [Related]
13. Astrocyte-specific overexpression of Nrf2 delays motor pathology and synuclein aggregation throughout the CNS in the alpha-synuclein mutant (A53T) mouse model.
Gan L; Vargas MR; Johnson DA; Johnson JA
J Neurosci; 2012 Dec; 32(49):17775-87. PubMed ID: 23223297
[TBL] [Abstract][Full Text] [Related]
14. α-Synuclein BAC transgenic mice exhibit RBD-like behaviour and hyposmia: a prodromal Parkinson's disease model.
Taguchi T; Ikuno M; Hondo M; Parajuli LK; Taguchi K; Ueda J; Sawamura M; Okuda S; Nakanishi E; Hara J; Uemura N; Hatanaka Y; Ayaki T; Matsuzawa S; Tanaka M; El-Agnaf OMA; Koike M; Yanagisawa M; Uemura MT; Yamakado H; Takahashi R
Brain; 2020 Jan; 143(1):249-265. PubMed ID: 31816026
[TBL] [Abstract][Full Text] [Related]
15. D409H GBA1 mutation accelerates the progression of pathology in A53T α-synuclein transgenic mouse model.
Kim D; Hwang H; Choi S; Kwon SH; Lee S; Park JH; Kim S; Ko HS
Acta Neuropathol Commun; 2018 Apr; 6(1):32. PubMed ID: 29703245
[TBL] [Abstract][Full Text] [Related]
16. Stress-inducible phosphoprotein 1 (HOP/STI1/STIP1) regulates the accumulation and toxicity of α-synuclein in vivo.
Lackie RE; de Miranda AS; Lim MP; Novikov V; Madrer N; Karunatilleke NC; Rutledge BS; Tullo S; Brickenden A; Maitland MER; Greenberg D; Gallino D; Luo W; Attaran A; Shlaifer I; Del Cid Pellitero E; Schild-Poulter C; Durcan TM; Fon EA; Duennwald M; Beraldo FH; Chakravarty MM; Bussey TJ; Saksida LM; Soreq H; Choy WY; Prado VF; Prado MAM
Acta Neuropathol; 2022 Nov; 144(5):881-910. PubMed ID: 36121476
[TBL] [Abstract][Full Text] [Related]
17. A53T-alpha-synuclein-overexpression in the mouse nigrostriatal pathway leads to early increase of 14-3-3 epsilon and late increase of GFAP.
Kurz A; May C; Schmidt O; Müller T; Stephan C; Meyer HE; Gispert S; Auburger G; Marcus K
J Neural Transm (Vienna); 2012 Mar; 119(3):297-312. PubMed ID: 21960009
[TBL] [Abstract][Full Text] [Related]
18. A prolyl oligopeptidase inhibitor, KYP-2047, reduces α-synuclein protein levels and aggregates in cellular and animal models of Parkinson's disease.
Myöhänen TT; Hannula MJ; Van Elzen R; Gerard M; Van Der Veken P; García-Horsman JA; Baekelandt V; Männistö PT; Lambeir AM
Br J Pharmacol; 2012 Jun; 166(3):1097-113. PubMed ID: 22233220
[TBL] [Abstract][Full Text] [Related]
19. NEDD4-mediated HSF1 degradation underlies α-synucleinopathy.
Kim E; Wang B; Sastry N; Masliah E; Nelson PT; Cai H; Liao FF
Hum Mol Genet; 2016 Jan; 25(2):211-22. PubMed ID: 26503960
[TBL] [Abstract][Full Text] [Related]
20. Applying chaperones to protein-misfolding disorders: molecular chaperones against α-synuclein in Parkinson's disease.
Chaari A; Hoarau-Véchot J; Ladjimi M
Int J Biol Macromol; 2013 Sep; 60():196-205. PubMed ID: 23748003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
